Kidney Week

Abstract: FR-PO449

CKD Patients Are Exposed to More Proton Pump Inhibitors (PPIs) Compared to Non-CKD Patients in a Tertiary Single Center

Session Information

• CKD: Risk Factors for Incidence and Progression - II
  November 03, 2017 | Location: Hall H, Morial Convention Center
  Abstract Time: 10:00 AM - 10:00 AM

Category: Chronic Kidney Disease (Non-Dialysis)

• 301 CKD: Risk Factors for Incidence and Progression

Authors

• Lee, Heejeong, Soon Chun Hyang University Hospital, SEOUL, Korea (the Republic of)

Heejeong Lee,

• Oh, Songhee, soon chun hyang university hospital, SEOUL, Korea (the Republic of)

Songhee Oh,

• Lee, Haekyung, Soonchunhyang University Hospital, SEOUL, Korea (the Republic of)

Haekyung Lee,

• Jeon, Jin seok, Soon Chun Hyang Univ. Hospital, Seoul, Korea (the Republic of)

Jin seok Jeon,

• Han, Dong-Cheol, Soon Chun Hyang University Hospital, SEOUL, Korea (the Republic of)

Dong-Cheol Han,

• Kwon, Soon hyo, Soon Chun Hyang University Hospital, SEOUL, Korea (the Republic of)

Soon hyo Kwon,

Background

Proton pump inhibitor (PPI) is associated with incident chronic kidney disease (CKD), CKD progression and end-stage renal disease (ESRD). However, the extent of PPI in CKD patients comparing to non CKD patients is still unclear.

Methods

We conducted a retrospective study on patients (>18 years old) who received PPI in a single tertiary center out-patient clinic (750 beds, Seoul, South Korea) from Jan. 2014 to Dec. 2015. PPIs need doctor’s prescription in South Korea. All data were collected from electronic medical record. The PPI prescription and their characteristics were analyzed according to CKD-EPI equation of the patients.

Results

Our sample consisted of 9,112 patients. Females were 50.3% were and CKD (eGFR<60mL/min) patients were 9.8%. Among CKD patients, 721 (7.9%) were categorized as stage 3 or 4, 176 (1.9%) were stage 5 or ESRD. Total 7 types of PPIs were prescribed. During the study period, median duration of PPI usage was 120days [interquartile range, 63-273] in CKD 3-4 group, 105 days [56-271] in CKD 5-ESRD group and 90 days [56-175] in non-CKD group. Patients with CKD stage 3 or 4 took longer duration of PPI than non-CKD paients (p<0.001). Main departments of medicine which prescribed PPIs in CKD group were gastroenterology (39.4%), cardiology (28.2%), nephrology (15.1%) and neurology (4.2%). Compared to the non-CKD group, the CKD stage 3 or 4 and CKD stage 5 orESRD group was taking more drugs simultaneously (6.9 ± 4.2 vs 4.5 ± 2.4; p<0.001 , 5.6 ± 2.8 vs 4.5 ± 2.4 ; p<0.0001, respectively).

Conclusion

CKD patients are exposed to more PPIs compared to non-CKD patients. Physicians should pay careful attention when prescribing PPIs in patients with CKD.